The results of the Phase I / II trial of the vaccine being developed by the University of Oxford in the United Kingdom offer encouraging data. The study published this Monday in the scientific journal The Lancet shows that there are no notable security problems and that it produces a strong immune response.
The vaccine causes a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus) and an antibody response within 28 days (the antibodies can neutralize the virus so it cannot infect cells when they initially contract).
The vaccine has not caused serious or adverse effects on the health of the participants
During the study, participants who received the vaccine had detectable neutralizing antibodies, and this response was strongest after a booster dose, as 100% of the participants' blood had neutralizing activity against the coronavirus.
The trial was carried out with 1,077 adult volunteers between 18 and 55 years old and only 10 of them received two doses that between April 23, 2020 and May 21, 2020, received the ChAdOx1 nCoV-19 vaccine or a MenACWY vaccine placebo.
The researchers found that a stronger immune response in the 10 participants who received two doses of the vaccine, indicating that this could be a good strategy for vaccination.
The next step in the vaccine study is to confirm that it can effectively protect against SARS-CoV-2 infection.
The University of Oxford is working with UK-based global biopharmaceutical company AstraZeneca for further development, large-scale manufacturing and potential distribution of the Covid-19 vaccine, with plans for clinical development and production of the vaccine worldwide. The project has been further boosted by $ 84 million in government funds to help accelerate its development.
"We are encouraged by the interim Phase I / II data showing that AZD1222 was able to generate a rapid antibody and T cell response against SARS-CoV-2." While there is more work to be done, today's data builds our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access worldwide, "says Mene Pangalos, executive vice president. Research and development of biopharmaceutical products at AstraZeneca.
AstraZeneca claims to be “committed to fulfilling its commitment to broad and equitable access to the vaccine”, should late-stage clinical trials be successful. So far, commitments to supply more than 2 billion doses of the vaccine have been agreed with the United Kingdom, the United States, the Alliance for Inclusive Vaccines of Europe (VAT), the Coalition for the Preparation of Epidemics ( CEPI), Gavi the Vaccine Alliance and the Indian Whey Institute.